Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

November 2013

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013

CRANBURY, N.J., Nov. 14, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2013.  Recent Highlights Bremelanotide development for Female Sexual Dysfunction (FSD): Successful completion …

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013 Read More »

Palatin Technologies Announces Option for License to Bremelanotide in Europe

CRANBURY, N.J., Nov. 13, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has entered into an option agreement for an exclusive license to bremelanotide for female sexual dysfunction indications in selected …

Palatin Technologies Announces Option for License to Bremelanotide in Europe Read More »

Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents

CRANBURY, N.J., Nov. 12, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office today issued two new patents to Palatin.  Both patents support Palatin’s program developing …

Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents Read More »

Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013

CRANBURY, N.J., Nov. 11, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2014 operating results on Thursday, November 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, …

Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013 Read More »

Scroll to Top